SGLT-2 inhibitors for people with type 2 diabetes.

dc.date.accessioned2019-12-06T20:57:42Z
dc.date.available2019-12-06T20:57:42Z
dc.date.created2019-12-06T20:57:42Z
dc.date.issued2019
dc.identifierhttps://hdl.handle.net/20.500.12866/7365
dc.identifierhttps://doi.org/10.1016/S0140-6736(19)30720-2
dc.description.abstractEvidence that sodium-glucose co-transporter-2 inhibitors (SGLT2i) can reduce cardiovascular risk—with trials showing reductions in cardiovascular death, myocardial infarction, and stroke—would suggest they have much to offer in the care of patients with type 2 diabetes at high risk of cardiovascular events. But should they be used in patients at low risk?...
dc.languageeng
dc.publisherElsevier
dc.relationLancet
dc.relation1474-547X
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectDiabetes Mellitus, Type 2
dc.subjectDipeptidyl-Peptidase IV Inhibitors
dc.subjectSodium-Glucose Transporter 2 Inhibitors
dc.subjectacetylsalicylic acid
dc.subjectacute heart failure
dc.subjectantidiabetic agent
dc.subjectcardiovascular disease
dc.subjectcause of death
dc.subjectDiabetes Mellitus, Type 2
dc.subjectdipeptidyl peptidase IV inhibitor
dc.subjectDipeptidyl-Peptidase IV Inhibitors
dc.subjectdisease course
dc.subjectgeriatric disorder
dc.subjectheart failure with preserved ejection fraction
dc.subjectheart failure with reduced ejection fraction
dc.subjectheart infarction
dc.subjecthuman
dc.subjectHumans
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectHypoglycemic Agents
dc.subjectintervention study
dc.subjectkidney function
dc.subjectLetter
dc.subjectmultiple chronic conditions
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectpatient care
dc.subjectpersonalized medicine
dc.subjectpriority journal
dc.subjectrisk factor
dc.subjectrisk reduction
dc.subjectsecondary prevention
dc.subjectSecondary Prevention
dc.subjectsodium glucose cotransporter 2 inhibitor
dc.subjectSodium-Glucose Transporter 2 Inhibitors
dc.titleSGLT-2 inhibitors for people with type 2 diabetes.
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución